
SUPPLEMENTARY FIGURES

Supplementary figure 1. A COnsolidated Standards Of Reporting Trials (CONSORT)


style diagram showing the patients and eyes included in the study.

Total of 157 eyes of 148 patients received first aflibercept injection for neovascular age-related macular degeneration between 1st September 2013 and 31^{st} February 2014	
I	3 eyes of 8 patients excluded due to loss of follow-up (no OCT data available for additional 19 eyes of 18 patients at the time of analysis) L eye of 1 patient excluded due to recurrence of pre-exciting intraocular nflammation
Total of 148 eyes of 139 patients included in visual acuity analysis of year 1 outcomes with 138 eyes of 130 patients included in analysis of OCT imaging	
$\downarrow \longrightarrow$	17 eyes of 16 patients excluded due to loss of follow-up (no OCT data available for additional 14 eyes of 13 patients at the time of analysis)
Total of 131 eyes of 123 patients included in visual acuity analysis of year 2 outcomes with 124 eyes of 117 patients included in analysis of OCT imaging	
$\downarrow \longrightarrow$	23 eyes of 21 patients excluded due to loss of follow-up (no OCT data available for additional 24 eyes of 22 patients at the time of analysis)
Total of 108 eyes of 102 patients included in visual acuity analysis of year 3 outcomes with 100 eyes of 95 patients included in analysis of OCT imaging	

Supplementary figure 2. Moorfields treatment protocol for aflibercept treatment for wet AMD.




Supplementary figure 3. A waterfall plot of the change in VA for each treated eye.



Supplementary figure 4. The frequency distribution of the injections in years 1,2 and

3.



Supplementary figure 5. The percentage of patients requiring less or more frequently injections than 8 weekly.

